. For the ENA 713 B352 Study. A randomised trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Ger Psychopharmacol 1998. 1(2): 155–65.


Please login to recommend the paper.


No Available Comments

Make a Comment

To make a comment you must login or register.

This paper appears in the following:


  1. Rivastigmine